This finding suggests that CPS, along with TPS, may serve as a sensitive and comprehensive marker for evaluating CD47—an innate immune checkpoint molecule—in ESCC, similar to how PD-1 expression is assessed in T cells. The gene discussed is CD47; the disease is esophageal squamous cell carcinoma.